Literature DB >> 9872731

A new CD44V3-containing isoform is involved in tumor cell growth and migration during human breast carcinoma progression.

E D Kalish1, N Iida, F L Moffat, L Y Bourguignon.   

Abstract

CD44 isoforms belong to a family of cell adhesion molecules expressed on the cell surface of many tumor cells during human breast cancer progression. In this study we have analyzed the expression of CD44v3-containing isoforms [containing heparan sulfate addition sites for growth factor binding] in primary breast tumors, axillary nodal metastases and normal breast tissue. Using reverse transcriptase-polymerase chain reaction (RT-PCR) followed by Southern blot, cloning, nucleotide sequencing and RT-in situ-PCR analyses, we have found that at least two CD44v3-containing isoforms, including one new species of CD44v2,deltav3-10 (deltav3 defined as a v3 exon lacking the first 24 base pairs) and another previously reported CD44v3,8-10 are preferentially expressed in human primary breast tumor and axillary nodal metastases but not in normal breast tissues. These finding suggest that these CD44v3-containing isoforms are closely associated with breast cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9872731     DOI: 10.2741/kalish

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  10 in total

Review 1.  Cancer stem cell detection and isolation.

Authors:  Meysam Moghbeli; Faezeh Moghbeli; Mohammad Mahdi Forghanifard; Mohammad Reza Abbaszadegan
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 2.  Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance.

Authors:  Steven J Wang; Lilly Y W Bourguignon
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 3.  CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.

Authors:  L Y Bourguignon
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

4.  Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells.

Authors:  Lilly Y W Bourguignon; Christina C Spevak; Gabriel Wong; Weiliang Xia; Eli Gilad
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

5.  CD44 variant isoforms in head and neck squamous cell carcinoma progression.

Authors:  Steven J Wang; Gabriel Wong; Anne-Martine de Heer; Weiliang Xia; Lilly Y W Bourguignon
Journal:  Laryngoscope       Date:  2009-08       Impact factor: 3.325

Review 6.  CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells.

Authors:  Linda T Senbanjo; Meenakshi A Chellaiah
Journal:  Front Cell Dev Biol       Date:  2017-03-07

7.  CD44v3,8-10 is essential for Slug-dependent vimentin gene expression to acquire TGF-β1-induced tumor cell motility.

Authors:  Shichao Qiu; Makoto Iimori; Keitaro Edahiro; Yoshiaki Fujimoto; Kazuaki Matsuoka; Eiji Oki; Yoshihiko Maehara; Masaki Mori; Hiroyuki Kitao
Journal:  Cancer Sci       Date:  2022-06-08       Impact factor: 6.518

8.  DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration.

Authors:  Joji Iida; Rebecca Clancy; Jesse Dorchak; Richard I Somiari; Stella Somiari; Mary Lou Cutler; Richard J Mural; Craig D Shriver
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

9.  CD44v3+/CD24- cells possess cancer stem cell-like properties in human oral squamous cell carcinoma.

Authors:  Keita Todoroki; Sachiko Ogasawara; Jun Akiba; Masamichi Nakayama; Yoshiki Naito; Naoko Seki; Jingo Kusukawa; Hirohisa Yano
Journal:  Int J Oncol       Date:  2015-11-20       Impact factor: 5.650

Review 10.  Epigenetic Regulation of the Biosynthesis & Enzymatic Modification of Heparan Sulfate Proteoglycans: Implications for Tumorigenesis and Cancer Biomarkers.

Authors:  Elizabeth E Hull; McKale R Montgomery; Kathryn J Leyva
Journal:  Int J Mol Sci       Date:  2017-06-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.